IMNN-001 (TheraPlas™-IL-12)
Advanced Ovarian Cancer (Epithelial Ovarian Cancer)
Phase 2Active clinical development
Key Facts
Indication
Advanced Ovarian Cancer (Epithelial Ovarian Cancer)
Phase
Phase 2
Status
Active clinical development
Company
About IMUNON
IMUNON is focused on developing new medicines that harness the body's immune system using DNA-based technology. The company's core platforms, TheraPlas™ for immuno-oncology and PlaCCine for infectious disease vaccines, aim to generate potent, targeted immune responses. With a seasoned leadership team and a pipeline targeting significant unmet medical needs, IMUNON is advancing its clinical programs while exploring broader applications for its synthetic DNA delivery systems.
View full company profile